Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies

M Stamelou, G Respondek, N Giagkou… - Nature Reviews …, 2021 - nature.com
Tauopathies are classified according to whether tau deposits predominantly contain tau
isoforms with three or four repeats of the microtubule-binding domain. Those in which four …

Molecular pathology of neurodegenerative diseases: principles and practice

GG Kovacs - Journal of clinical pathology, 2019 - jcp.bmj.com
Neurodegenerative diseases are characterised by selective dysfunction and progressive
loss of synapses and neurons associated with pathologically altered proteins that deposit …

[HTML][HTML] Clinical effects of Lewy body pathology in cognitively impaired individuals

C Quadalti, S Palmqvist, S Hall, M Rossi… - Nature Medicine, 2023 - nature.com
There is poor knowledge about the clinical effects of Lewy body (LB) pathology in patients
with cognitive impairment, especially when coexisting with Alzheimer's disease (AD) …

Novel tau filament fold in corticobasal degeneration

W Zhang, A Tarutani, KL Newell, AG Murzin… - Nature, 2020 - nature.com
Corticobasal degeneration (CBD) is a neurodegenerative tauopathy—a class of disorders in
which the tau protein forms insoluble inclusions in the brain—that is characterized by motor …

[HTML][HTML] Distribution patterns of tau pathology in progressive supranuclear palsy

GG Kovacs, MJ Lukic, DJ Irwin, T Arzberger… - Acta …, 2020 - Springer
Progressive supranuclear palsy (PSP) is a 4R-tauopathy predominated by subcortical
pathology in neurons, astrocytes, and oligodendroglia associated with various clinical …

[HTML][HTML] Tau deposition patterns are associated with functional connectivity in primary tauopathies

N Franzmeier, M Brendel, L Beyer, L Slemann… - Nature …, 2022 - nature.com
Tau pathology is the main driver of neuronal dysfunction in 4-repeat tauopathies, including
cortico-basal degeneration and progressive supranuclear palsy. Tau is assumed to spread …

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

GU Höglinger, I Litvan, N Mendonca, D Wang… - The Lancet …, 2021 - thelancet.com
Background Progressive supranuclear palsy is a neurodegenerative disorder associated
with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds …

Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy

M Brendel, H Barthel, T van Eimeren, K Marek… - JAMA …, 2020 - jamanetwork.com
Importance Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific
tau aggregates establish the neuropathologic diagnosis of definite PSP post mortem. Future …

[HTML][HTML] Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy …

ML Malarte, PG Gillberg, A Kumar, N Bogdanovic… - Molecular …, 2023 - nature.com
Recent mechanistic and structural studies have challenged the classical tauopathy
classification approach and revealed the complexity and heterogeneity of tau pathology in …

[HTML][HTML] Mitochondrial calcium deregulation in the mechanism of beta-amyloid and tau pathology

N Esteras, AY Abramov - Cells, 2020 - mdpi.com
Aggregation and deposition of β-amyloid and/or tau protein are the key neuropathological
features in neurodegenerative disorders such as Alzheimer's disease (AD) and other …